Molecular mechanisms in allergy and clinical immunology: Antigen-presenting cells in allergy

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 3, 2001, Pages 329-339

  Von Bubnoff, Dagmar ^a   Geiger, Elisabeth ^a   Bieber, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Atopic dermatitis; Dendritic cell; Fc RI

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E RECEPTOR;

ALLERGY; ANTIGEN PRESENTING CELL; ATOPY; CELL MIGRATION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LANGERHANS CELL; MACROPHAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; BIOLOGICAL MODEL; HYPERSENSITIVITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY;

ANTIGEN-PRESENTING CELLS; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; MODELS, IMMUNOLOGICAL; RECEPTORS, IGE;

EID: 0035459690     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.117457     Document Type: Article

References (75)

1. Allergy-associated polymorphisms of the Fc epsilon RI beta subunit do not impact its two amplification functions
2. Atopy and asthma: Genetic variants of IL-4 and IL-13 signalling
3. Fc epsilon RI expressing dendritic cells: The missing link in the pathophysiology of atopic dermatitis
4. Atopic dermatitis: The skin as a window into the pathogenesis of chronic allergic diseases
5. Dendritic cells and the control of immunity
6. Dendritic cells: From ignored cells to major players in T-cell-mediated immunity
7. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes
8. Functions of Fc receptors on human dendritic Langerhans cells
9. Fc epsilon RI-expressing antigen-presenting cells: New players in the atopic game
10. The presence of IgE on macrophages and dendritic cells infiltrating into the skin lesion of atopic dermatitis
11. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI)
12. Cross-linking of monocyte plasma membrane Fc alpha, Fc gamma or mannose receptors induces TNF production
13. Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation
14. Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (Pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-dc2
15. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature
16. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?
17. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand
18. Plasmacytoid monocytes express IL3-receptor alpha and differentiate into dendritic cells
19. Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells
20. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha
21. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
22. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
23. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors
24. Phenotypic analysis of IL-10-treated macrophages using the monoclonal antibodies RFD1 and RFD7
25. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation
26. Immune mechanisms in contact allergic dermatitis
27. CCR7 expression and memory T cell diversity in humans
28. Chemokine receptor expression and function in CD4(+) T lymphocytes with regulatory activity
29. Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance
30. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
31. Mobilizing dendritic cells for tolerance, priming and chronic inflammation
32. Functional diversity of helper T lymphocytes
33. Reciprocal control of T helper cell and dendritic cell differentiation
34. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
35. Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells
36. Increased circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)+ type 2 cytokine-producing cells, and decreased CLA+ type 1 cytokine-producing cells in atopic dermatitis
37. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
38. Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI
39. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions
40. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions
41. Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells
42. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
43. Epidemiological study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy: Phenotype issues
44. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: Downregulation by inhaled corticosteroids
45. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation
46. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice
47. Immunological/physiological relationships in asthma: Potential regulation by lung macrophages
48. Macrophages and allergic lung disease
49. Decreased suppressor cell activity of alveolar macrophages in bronchial asthma
50. Leukocyte activation in allergen-induced late-phase asthmatic reactions
51. Asthma
52. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
53. Langerhans cells in nasal mucosa of patients with grass pollen allergy
54. Characterization and quantification of cellular infiltrates in nasal mucosa of patients with grass pollen allergy, non-allergic patients with nasal polyps and controls
55. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema
56. Fc epsilon RI on human epidermal Langerhans cells: An old receptor with new structure and functions
57. Expression of the high-affinity receptor for IgE (Fc epsilon RI) on human Langerhans cells: The end of a dogma
58. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
59. New insights in the structure and biology of the high affinity receptor for IgE (Fc epsilon RI) on human epidermal Langerhans cells
60. Regulation of the high affinity receptor for IgE on human epidermal Langerhans cells
61. The role of dendritic cells in contact hypersensitivity
62. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity
63. Contact dermatitis II. Clinical aspects and diagnosis
64. Contact dermatitis I. Pathophysiology of contact sensitivity
65. Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity
66. Allergy and allergic diseases. Second of two parts
67. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early treatment of the Atopic Child
68. Treatment of allergic asthma with monoclonal anti-IgE antibody
69. Gene vaccination: Plasmid DNA is more than just a blueprint
70. Long-term clinical efficacy of grass-pollen immunotherapy
71. A short-term trial of tacrolimus ointment for atopic dermatitis
72. Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis
73. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis
74. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
75. New technologies to prevent and treat contact hypersensitivity responses